These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 6083935

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bone destruction in myelogenous marrow crisis.
    Braunstein EM, Hammond B, Schnitzer B.
    J Can Assoc Radiol; 1980 Mar; 31(1):69-70. PubMed ID: 6928852
    [Abstract] [Full Text] [Related]

  • 4. [Osteolytic lesions in chronic myeloid leukemia. Report of three cases (author's transl)].
    Juncá Piera J, Durán Suárez JR, Triginer Boixeda J.
    Med Clin (Barc); 1981 Mar 25; 76(6):259-61. PubMed ID: 6942204
    [Abstract] [Full Text] [Related]

  • 5. [Bone destructive foci as precursors of the blastic crisis in chronic myelocytic leukemia].
    Cavalli F, Pedrinis E, Mombelli G, Goldhirsch A, Reiner M.
    Schweiz Med Wochenschr; 1977 Jun 25; 107(25):872-5. PubMed ID: 268024
    [Abstract] [Full Text] [Related]

  • 6. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
    Derderian PM, Kantarjian HM, Talpaz M, O'Brien S, Cork A, Estey E, Pierce S, Keating M.
    Am J Med; 1993 Jan 25; 94(1):69-74. PubMed ID: 8420302
    [Abstract] [Full Text] [Related]

  • 7. Terminal-phase chronic myelogenous leukemia: approaches to treatment.
    Allen SL, Coleman M.
    Cancer Invest; 1985 Jan 25; 3(5):491-503. PubMed ID: 3902166
    [Abstract] [Full Text] [Related]

  • 8. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
    Liu YL, Wang XN, Liu HS.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun 25; 22(3):629-33. PubMed ID: 24989266
    [Abstract] [Full Text] [Related]

  • 9. Idarubicin in blastic crisis of chronic myelogenous leukemia.
    Lambertenghi-Deliliers G, Annaloro C, Cortellaro M, Pozzoli E, Oriani A, Polli EE.
    Haematologica; 1991 Jun 25; 76(5):406-8. PubMed ID: 1806446
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S, Picardi A, Fazi P, Testi AM, Petti MC, Montefusco E, Mandelli F.
    Leukemia; 1996 May 25; 10(5):766-8. PubMed ID: 8656669
    [Abstract] [Full Text] [Related]

  • 11. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM, Chimirri F, Podestà M, Pitto A, Piaggio G, Dejana A, Lerma E, Pollicardo N, Vassallo F, Soracco M, Benvenuto F, Valbonesi M, Carlier P, Vimercati R, Prencipe E, Gatti AM, Ferrara RA, Incagliato M, Florio G, Frassoni F.
    Bone Marrow Transplant; 1996 Feb 25; 17(2):201-5. PubMed ID: 8640167
    [Abstract] [Full Text] [Related]

  • 12. [Chemotherapy of chronic myelogenous leukemia in blastic crisis--vindesine, cytosine arabinoside prednisolone combination therapy].
    Uzuka Y, Saito Y, Takahash H, Komatsu M.
    Gan To Kagaku Ryoho; 1984 May 25; 11(5):1064-70. PubMed ID: 6586112
    [Abstract] [Full Text] [Related]

  • 13. Osteolysis in chronic myeloid leukemia.
    Lambertenghi-Deliliers G, Castagnone D, Porro F, Cortelezzi A.
    Tumori; 1978 Apr 30; 64(2):175-81. PubMed ID: 276965
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pathological fracture as a manifestation of extramedullary blastic crisis in chronic myelogenous leukemia: report of one case.
    Yu HH, Lu MY, Lin DT, Lin KH, Tang JL, Jou ST.
    Acta Paediatr Taiwan; 2006 Apr 30; 47(3):150-4. PubMed ID: 17078470
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
    Katagiri T, Miyazawa K, Uchida Y, Hayashi S, Iwama H, Shyohji N, Kawakubo K, Shimamoto T, Inatomi Y, Kuriyama Y, Yaguchi M, Nehashi Y, Ohyashiki K, Toyama K.
    Rinsho Ketsueki; 1998 Dec 30; 39(12):1149-56. PubMed ID: 10028846
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.